A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

Matthew R. Henn, Edward J. O’Brien, Liyang Diao, Brian G. Feagan, William J. Sandborn, Curtis Huttenhower, Jennifer R. Wortman, Barbara McGovern, Sherry Wang‐Weigand, David I. Lichter, Meghan Chafee, Christopher B. Ford, Patricia Bernardo, Peng Zhao, Sheri L. Simmons, Amelia D. Tomlinson, David N. Cook, Roger J. Pomerantz, Bharat Misra, John Auniņš, Michele Trucksis